These findings indicate optionally generic applicability of these concepts which will now be extended to other types MPN by using available in silico data complemented by newly generated “-omics” data on well-defined subpopulations of patient cells. Results will be validated clinically within the SAL-MPN registry as well as clinical prospective trials.
Selected references: